M&A Deal Summary

Gilead Sciences Acquires Raylo Chemicals

On June 6, 2006, Gilead Sciences acquired chemicals company Raylo Chemicals from Degussa AG for 115M EUR

Acquisition Highlights
  • This is Gilead Sciences’ 1st transaction in the Chemicals sector.
  • This is Gilead Sciences’ 18th largest (disclosed) transaction.
  • This is Gilead Sciences’ 1st transaction in Canada.
  • This is Gilead Sciences’ 1st transaction in Alberta.

M&A Deal Summary
Date 2006-06-06
Target Raylo Chemicals
Sector Chemicals
Buyer(s) Gilead Sciences
Sellers(s) Degussa AG
Deal Type Divestiture
Deal Value 115M EUR

Target

Raylo Chemicals

Edmonton, Alberta, Canada
Raylo Chemicals, Inc. is a manufacturer of active pharmaceutical ingredients.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Gilead Sciences

Foster City, California, United States
Category Company
Founded 1987
Sector Life Science
Employees18,000
Revenue 27.1B USD (2023)
DESCRIPTION
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.

DEAL STATS #
Overall 3 of 24
Sector (Chemicals) 1 of 1
Type (Divestiture) 1 of 2
State (Alberta) 1 of 1
Country (Canada) 1 of 2
Year (2006) 1 of 3
Size (of disclosed) 18 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-01-23 Triangle Pharmaceuticals

Durham, North Carolina, United States

Triangle Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing effective solutions for serious viral disease, with a particular focus on therapies for the human immunodeficiency virus (HIV), including the acquired immunodeficiency syndrome (AIDS) and the hepatitis B virus (HBV).

Buy $464M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-08-11 Corus Pharma

Seattle, Washington, United States

Corus Pharma is committed to developing and commercializing specialty products for respiratory and infectious diseases that can help provide improved health and superior quality of life.

Buy $365M

Seller(S) 1

SELLER

Degussa AG

Dusseldorf, Germany
Category Company
Sector Chemicals
DESCRIPTION

Degussa AG manufactures chemicals,acids. Degussa is the global market leader in specialty chemicals. Its business is creating essentials innovative products and system solutions that make indispensable contributions to its customers' success.

DEAL STATS #
Overall 6 of 6
Sector (Chemicals) 4 of 4
Type (Divestiture) 4 of 4
State (Alberta) 1 of 1
Country (Canada) 1 of 1
Year (2006) 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-09-09 Food Ingredients Business / Degussa

Germany

Degussa's Food Ingredients Business Unit consists of the Texturant Systems and Flavors Business Lines. Texturant Systems is comprised of product groups in the areas of hydrocolloids, blends, lecithin, cultures and bioactive ingredients.

Sell €540M
Mergr

Product

Company

Legal